Hyderabad-based Suven Life Sciences has won four product patents for its new chemical entities designed for treatment of neurodegenerative diseases.
These were granted in Europe, Sri Lanka and South Korea for compounds that are being developed as therapeutic agents for Alzheimer's disease, Parkinson's and Schizophrenia, among others.
Suven Life CEO Venkat Jasti said the cognitive disorders for which these drugs would be developed were a $ 30-billion market globally. With this, the biopharma company has a total of 11 granted patents from Europe, eight from Sri Lanka and five from South Korea.
The company said these patents are its exclusive intellectual property, achieved through internal research. Products developed out of these inventions may be outlicensed at different phases of clinical development, it said in a release on Thursday.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app